… of allosteric inhibitors and other kinases inhibitors can … SHP2 inhibitors and revisited the
SHP2-targeted anticancer strategies, and combination therapies with other PTK inhibitors …

… targeted therapies that include an inhibitor of SHP2, a protein tyrosine phosphatase. SHP2
… multiple mechanisms: dephosphorylation of inhibitory tyrosine phosphorylation on positive …

… makes SHP2 a promising target for drug development. In the following section, we summarize
SHP2 inhibitors … protein could be a novel approach to enhance other targeted therapies for …

… and functions of SHP2, and briefly review the development of SHP2 inhibitors. Importantly, …
using SHP2 inhibitors. We also discuss the future clinical applications of SHP2 inhibitors, …

… A potent, highly specific inhibitor targeting SHP2, SHP099, … would inhibit signals from RTKs
activated following MEK inhibition … Our results suggest that SHP2 inhibition could provide a …

… , eight SHP2 inhibitors have advanced into clinical trials as mono- or combined therapy for
… In this Perspective, we briefly summarize the strategies targeting SHP2 including inhibitors, …

… To further identify whether targeting SHP2 can inhibit metastatic tumor growth we implemented
an … targeted therapies, our studies strongly support development of this combined …

… The collective preclinical data and these early clinical findings support the continued
combination testing of current targeted therapies together with allosteric SHP2 inhibitors in RAS-…

… studies performed with allosteric SHP2 inhibitors and combination treatments of SHP2 … in
these complex signaling pathways will help us improve targeted therapy for SHP2, as well as …

… SHP2 inhibition offers a promising therapeutic strategy as a means to prevent RTK-driven
adaptive and acquired resistance to targeted therapy. SHP2 inhibition enhances the efficacy of …